Qualigen Therapeutics, Inc. (NASDAQ:AIXC) Sees Significant Growth in Short Interest

Qualigen Therapeutics, Inc. (NASDAQ:AIXC) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 162,797 shares, an increase of 104.6% from the June 15th total of 79,560 shares. Based on an average daily volume of 263,099 shares, the short-interest ratio is presently 0.6 days. Currently, 0.8% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Qualigen Therapeutics in a research note on Friday, April 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Qualigen Therapeutics Stock Down 0.3%

Shares of NASDAQ:AIXC traded down $0.00 during trading on Friday, reaching $0.88. 6,242 shares of the company were exchanged, compared to its average volume of 73,493. The business’s fifty day simple moving average is $1.23. Qualigen Therapeutics has a 12-month low of $0.85 and a 12-month high of $8.81. The company has a market capitalization of $17.75 million, a price-to-earnings ratio of -0.13 and a beta of 0.49.

Qualigen Therapeutics (NASDAQ:AIXC) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.